WHI TRUST Co LLC Takes Position in Kalaris Therapeutics Inc. $KLRS

WHI TRUST Co LLC acquired a new stake in Kalaris Therapeutics Inc. (NASDAQ:KLRS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 97,493 shares of the company’s stock, valued at approximately $823,000. Kalaris Therapeutics accounts for about 0.6% of WHI TRUST Co LLC’s investment portfolio, making the stock its 11th biggest position. WHI TRUST Co LLC owned approximately 0.52% of Kalaris Therapeutics as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Woodline Partners LP bought a new position in shares of Kalaris Therapeutics in the third quarter valued at about $1,394,000. Bridgeway Capital Management LLC bought a new position in shares of Kalaris Therapeutics in the third quarter valued at about $130,000. XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics in the second quarter valued at about $65,000. Johnson Financial Group Inc. bought a new position in shares of Kalaris Therapeutics in the third quarter valued at about $58,000. Finally, Belpointe Asset Management LLC bought a new position in shares of Kalaris Therapeutics in the third quarter valued at about $231,000. 66.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

KLRS has been the topic of a number of recent research reports. Wedbush initiated coverage on shares of Kalaris Therapeutics in a research report on Thursday. They set an “outperform” rating and a $17.00 price target on the stock. Morgan Stanley initiated coverage on shares of Kalaris Therapeutics in a research report on Thursday, April 16th. They set an “overweight” rating and a $14.00 price target on the stock. Citizens Jmp lowered their price target on shares of Kalaris Therapeutics from $26.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Kalaris Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Kalaris Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $15.60.

Kalaris Therapeutics Stock Up 8.1%

Shares of Kalaris Therapeutics stock opened at $5.22 on Friday. The company has a market capitalization of $120.02 million, a price-to-earnings ratio of -2.43 and a beta of 0.15. Kalaris Therapeutics Inc. has a 12-month low of $2.14 and a 12-month high of $11.88. The firm’s 50-day moving average price is $6.58 and its two-hundred day moving average price is $7.52.

Kalaris Therapeutics (NASDAQ:KLRS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06. On average, sell-side analysts expect that Kalaris Therapeutics Inc. will post -2.15 earnings per share for the current year.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.